ClinicalTrials.gg
RecruitingNCT04489238Updated Oct 23, 2026

Collection of Information to Better Understand Young Onset Colorectal Cancer

An observational study in Colorectal Cancer and Colorectal Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.
Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,366
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
Largest of 21
1,366 · median 110
Started
2020
with 1 other
Observational
21 of 69
5 open now
Primary completion
2027-07
later than 6 of 17 live
Registered
57th of 69
by date

Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one has the largest planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2020, is one of 21 observational ones, reaches primary completion later than 6 of the 17 other live ones, and was the 57th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this registry study is to create a database-a collection of information-for better understanding young onset colorectal cancer. Colorectal cancer patients are considered to have young onset colorectal cancer if they are diagnosed with their cancer before the age of 50. Researchers will use the information from this database to learn more about how young onset colorectal cancer may be similar to or different from colorectal cancer that is diagnosed later in life. Researchers will also use information from the database for current and future research on young onset colorectal cancer.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Carcinoma

Keywords

  • young onset colorectal cancer
  • colorectal registry
  • 20-315
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Potential research subjects will be identified through the Center for Young Onset Gastrointestinal Cancer, a member of the patient's treatment team, the principal investigator, or research team at Memorial Sloan Kettering Cancer Center (MSKCC). All study participants will be recruited from patients under the care of consenting professionals. If the investigator is a member of the treatment team, s/he will screen their patient's medical records for suitable research study participants and discuss the study and their potential for enrolling in the research study. Potential subjects contacted by their treating physician will be referred to the investigator/research staff of the study.

Eligibility criteria

Inclusion Criteria:

Participant Inclusion Criteria for database and questionnaire (YOGI)

  • Histological or cytological diagnosis of gastrointestinal cancer
  • 18 - 49 years old at time of consent
  • No Known hereditary CRC or other cancer predisposition syndrome (stool collection cohort only)
  • No history of inflammatory bowel disease (stool collection cohort only)
  • No prior diagnosis of gastrointestinal cancer (stool collection cohort only)

Participant Inclusion Criteria for database and questionnaire (Controls)

  • Histological or cytological diagnosis of colorectal adenocarcinoma
  • No previous treatment for CRC (including surgery, chemotherapy, immunotherapy or radiation)
  • Age 50 or older at time of consent
  • No Known hereditary CRC or other cancer predisposition syndrome
  • No history of inflammatory bowel disease
  • No prior diagnosis of CRC
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,366 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Young onset Colorectal Cancer Participants

    (Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.

    Other: Risk Factor Questionnaire

  • Average onset Colorectal Cancer Participants

    (Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls. Stool collection cohort only.

    Other: Risk Factor Questionnaire

Interventions

  • OtherRisk Factor Questionnaire

    Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit

    Also known as: CYOC Risk Factor Questionnaire

06

What researchers measure

Primary outcomes

  1. Establish a prospective database of patients with Young Onset Colorectal Cancer

    from diagnosis through survivorship

    Time frame: 1 year

07

Study locations

8 of 8 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Andrea Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
    Recruiting
    • Andrea Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
    Recruiting
    • Andrea Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Cancer Center @ Commack
    Commack, New York 11725, United States
    Recruiting
    • Andrea Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
    Recruiting
    • Andrew Cercek, MD · Contact646-888-4189
  • MSK at Ralph Lauren
    New York, New York 10035, United States
    Recruiting
    • Andrew Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Andrew Cercek, MD · Contact646-888-4189
  • Memorial Sloan Kettering Nassau
    Rockville Centre, New York 11553, United States
    Recruiting
    • Andrea Cercek, MD · Contact646-888-4189
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jul 2027, 84 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 84 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2020
First posted
Jul 28, 2020
StartActual
Jul 22, 2020
Primary completionEst.
Jul 22, 2027was Jul 2026
CompletionEst.
Jul 22, 2027was Jul 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 22, 2026→Jul 22, 2027
Oct 23, 2026
Study completion
Jul 22, 2026→Jul 22, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jul 22, 2026→Jul 22, 2027
    Study completion Jul 22, 2026→Jul 22, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04489238
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
Jul 22, 2020
Primary completion
Jul 22, 2027 (estimated)
Completion
Jul 22, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Andrea Cercek, MD
Contact
cerceka@mskcc.org
646-888-4189
Rona Yaeger, MD
Contact
yaegerr@mskcc.org
646-888-5109
Andrea Cercek, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion